Reduced-dose RT with Cisplatin improves outcomes for HPV-associated oropharyngeal carcinoma
Children prioritize what they hear over what they see when gauging emotional aspects of their experience
29 January 2021Another deadly disease for smokers: Pulmonary fibrosis
29 January 2021Reduced-dose RT with Cisplatin improves outcomes for HPV-associated oropharyngeal carcinoma
A combination of reduced-dose radiotherapy using intensity-modulated radiotherapy (IMRT) combined with concurrent cisplatin met the threshold for disease control and quality of life compared to the standard of care for good-risk patients with HPV-associated oropharyngeal squamous cell carcinoma on the NRG Oncology clinical trial NRG-HN002. The outcomes from this data justify the advancement of the reduced radiotherapy dose with cisplatin to a Phase III clinical trial setting in this population. These results were recently published in the Journal of Clinical Oncology.
